Comparison of the efficacy and safety of infliximab, as monotherapy or in combination with azathioprine, versus azathioprine monotherapy in moderate to severe active ulcerative colitis (part 1) comparison of maintenance versus intermittent infliximab treatment in maintaining remission: a follow-up of efficacy and safety (part 2).

Trial Profile

Comparison of the efficacy and safety of infliximab, as monotherapy or in combination with azathioprine, versus azathioprine monotherapy in moderate to severe active ulcerative colitis (part 1) comparison of maintenance versus intermittent infliximab treatment in maintaining remission: a follow-up of efficacy and safety (part 2).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Azathioprine; Infliximab
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms UC SUCCESS
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 26 Oct 2011 Results presented at the 19th United European Gastroenterology Week.
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 01 Feb 2010 Primary endpoint 'Remission-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top